Effective Oversight, Safety Will Be Critical to the Success of India’s Weight-Loss Drug Revolution
On March 20, a significant moment in the global pharmaceutical industry passed with little public notice. The patent on semaglutide, the molecule behind Danish pharma major Novo Nordisk’s blockbuster weight-loss drugs Ozempic and Wegovy, expired in India. Indian pharmaceutical companies, which had spent the past year ramping up manufacturing capabilities in anticipation of this date, are now poised to launch domestically produced generic injectable and oral formulations of semaglutide. Building on India’s established capabilities as a producer of cost-effective generic drugs, these new products are expected to hit the market soon. The entry of major drug companies like Cipla, Sun Pharma, Dr Reddy’s Laboratories, Biocon, Natco, Zydus, and Mankind Pharma could cause prices to plummet by 50 to 70 per cent. For millions of overweight Indians and those suffering from Type 2 diabetes, this is a moment of immense promise.
The potential market is staggering. According to the National Family Health Survey 2019-21, 24 per cent of Indian women and 23 per cent of Indian men are overweight. Beyond this, some 77 million Indians suffer from Type 2 diabetes. Both are considered “lifestyle” diseases, the product of carb- and oil-heavy diets and inadequate exercise. Both diseases offer domestic manufacturers of generics large addressable markets. The market has already grown rapidly—from $16 million in 2021 to $100 million in 2025. It is expected to grow eightfold by 2030. For Indian patients, the prospect of accessing these life-altering drugs at a fraction of the current cost is a genuine breakthrough.
But easier accessibility and greater affordability also carry significant risks. The most pressing concern is quality. Novo Nordisk’s patents in Europe and the United States—India’s biggest export markets for generics—will expire only in 2031. This means that for the next five years, Indian generic manufacturers will be competing intensely in the domestic market, without the oversight that comes from exporting to highly regulated Western markets. Had these generics been destined for the US or Europe, the imposition of global standards under bodies like the US Food and Drug Administration would have ensured minimum standards of safety and efficacy. But the recent scandals over Indian-manufactured cough syrups, which caused the deaths of children in Central Asia and Africa, point to the gross inadequacy of drug regulation in this country. The spectre of those tragedies haunts this new opportunity.
Indian generic manufacturers bear a heavy responsibility in ensuring the safety of their products. This responsibility is compounded by the fact that a large proportion of these generics will likely be subcontracted in response to anticipated demand surges. The Indian pharmaceutical industry has a complex supply chain, with many small and medium-sized manufacturers producing ingredients and finished products for larger players. When demand spikes, the pressure to cut corners, to source cheaper inputs, to expedite production processes, increases exponentially. The danger of rampant counterfeiting—one of the Indian pharma business’s most chronic and underestimated weaknesses—cannot be ignored. By one estimate, nearly 28 per cent of the drugs available in urban India could be spurious. High-demand, high-value drugs such as antibiotics or those for cardiac and cancer treatment are counterfeiters’ principal targets. Weight-loss drugs, with their blockbuster potential and high consumer demand, could well join this list.
The Indian proclivity to self-medicate and access prescription drugs over the counter adds another layer of risk. Medical practitioners have repeatedly asserted that semaglutide and similar drugs need to be administered with a strict diet and exercise regimen to work effectively and must be taken under strong medical supervision. They are not magic bullets; they are powerful tools that, when used correctly, can produce remarkable results. But when used incorrectly, they can cause serious harm. Yet today, even before the generics have hit the market, the drug is being prescribed not just by endocrinologists and cardiologists but also by gym instructors and beauticians with scant knowledge of patient physiology or the authority to do so. The temptation for increasingly obese Indians to opt for a cheap jab without proper medical examination is almost a foregone conclusion.
The consequences of such misuse could be severe. Semaglutide works by mimicking a hormone that regulates appetite. It can cause nausea, vomiting, diarrhoea, and other gastrointestinal side effects. In rare cases, it can lead to more serious complications, including pancreatitis, gallbladder disease, and kidney problems. When taken without proper medical oversight, when combined with other medications, or when used by individuals with underlying health conditions that have not been identified, the risks multiply. The promise of a quick fix, of shedding pounds with a simple injection, could lead to a public health crisis of its own.
The success of Indian branded weight-loss drugs in the domestic market will determine their ability to break into the lucrative markets of the West when patents expire after just five years. This is a critical window. If Indian manufacturers can demonstrate that they can produce safe, effective, and affordable generics that meet the highest quality standards, they will be well-positioned to compete globally. But if the domestic rollout is marred by quality failures, by counterfeiting scandals, or by a wave of adverse events resulting from unsupervised use, the reputation of Indian generics will be set back for years, if not decades.
What, then, must be done? First, drug regulators at the Central Drugs Standard Control Organization (CDSCO) must step up. The regulatory apparatus that failed to prevent the cough syrup tragedies must be strengthened. Random testing of batches, surprise inspections of manufacturing facilities, and swift action against violators are essential. The temptation to turn a blind eye to quality lapses in the rush to capture market share must be resisted.
Second, the medical community must take responsibility. Endocrinologists, cardiologists, and general practitioners must educate their patients about the proper use of these drugs. They must resist the pressure to prescribe them casually, to treat them as a consumer good rather than a serious medical intervention. Professional medical associations should issue clear guidelines on who should be prescribed these drugs, under what conditions, and with what follow-up.
Third, the phenomenon of over-the-counter availability must be addressed. Prescription drugs should not be available without a prescription. This requires enforcement at the level of pharmacies, but also a public awareness campaign to educate consumers about the dangers of self-medication. The same advertising and marketing budgets that will be used to promote these drugs should be used to promote responsible use.
Fourth, the industry itself must act. The large pharmaceutical companies that will be marketing these generics have a commercial interest in ensuring the safety of their products. A single scandal can wipe out years of brand building. They must invest in supply chain integrity, in quality control, and in post-marketing surveillance. They must not subcontract to manufacturers who cannot meet the highest standards.
Finally, the government must prepare for the consequences of wider access. If these drugs are as effective as promised, and if they are as affordable as expected, demand will be immense. This is a good problem to have, but it is a problem nonetheless. The government must ensure that the healthcare system is ready to support patients who use these drugs, that adverse events are reported and investigated, and that the benefits of this pharmaceutical revolution are not overshadowed by preventable harms.
The expiration of the semaglutide patent in India is a moment of genuine opportunity. It is a chance to make a life-changing treatment accessible to millions. But it is also a test. The test is whether India can produce these drugs safely, regulate them effectively, and ensure they are used responsibly. The answers to these questions will determine not only the success of this particular class of drugs but the future of India’s generic pharmaceutical industry as a whole. The stakes could not be higher.
Questions and Answers
Q1: What is the significance of March 20 for India’s pharmaceutical industry?
A1: On March 20, the patent on semaglutide—the molecule behind blockbuster weight-loss drugs Ozempic and Wegovy—expired in India. This allows Indian generic manufacturers to produce and sell their own versions, potentially reducing prices by 50-70% and making these drugs accessible to millions of Indians suffering from obesity and Type 2 diabetes.
Q2: What are the main quality and safety concerns with the introduction of generic weight-loss drugs in India?
A2: The main concerns are:
-
Quality control: Recent scandals over Indian cough syrups that killed children abroad point to inadequate drug regulation in India.
-
Counterfeiting: An estimated 28% of drugs in urban India may be spurious, and high-demand drugs like these will be prime targets for counterfeiters.
-
Subcontracting: Much of the production will be subcontracted, increasing the risk of quality lapses in the supply chain.
Q3: What is the problem with how weight-loss drugs are currently being accessed in India?
A3: These drugs are being prescribed not just by qualified doctors (endocrinologists, cardiologists) but also by gym instructors and beauticians with no medical authority or knowledge of patient physiology. There is also a strong Indian proclivity to self-medicate and access prescription drugs over the counter, bypassing proper medical supervision.
Q4: Why is the next five-year window critical for Indian generic manufacturers of semaglutide?
A4: Patents in the US and Europe expire only in 2031. The next five years will determine whether Indian manufacturers can demonstrate that they can produce safe, effective, and affordable generics. Success in the domestic market will position them to break into the lucrative Western markets after 2031; failure could damage the reputation of Indian generics for years.
Q5: What are the key actions needed to ensure the safe rollout of generic weight-loss drugs in India?
A5: The article recommends:
-
Regulators (CDSCO): Must strengthen random testing, surprise inspections, and swift action against violators.
-
Medical community: Must issue guidelines and resist casual prescribing.
-
Enforcement: Prescription drugs should not be available over the counter.
-
Industry: Large manufacturers must invest in supply chain integrity and quality control.
-
Government: Must prepare for immense demand and ensure adverse events are reported and investigated.
